Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $68.9 million.

  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity rose 36.83% to $80.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.3 million, marking a year-over-year increase of 42.71%. This contributed to the annual value of $68.9 million for FY2024, which is 51.27% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Liabilities and Shareholders Equity of $68.9 million as of FY2024, which was up 51.27% from $45.6 million recorded in FY2023.
  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $68.9 million during FY2024, with a 5-year trough of $45.6 million in FY2023.
  • For the 3-year period, Corvus Pharmaceuticals' Liabilities and Shareholders Equity averaged around $60.9 million, with its median value being $68.2 million (2022).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 33.25% in 2023, then spiked by 51.27% in 2024.
  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $68.2 million in 2022, then crashed by 33.25% to $45.6 million in 2023, then spiked by 51.27% to $68.9 million in 2024.